3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
4
Phase 2
3
Phase 3
1
Status
Withdrawn
2
Completed
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Lymphoid
3
Other hematologic neoplasm
1
Conditions
Lymphoma, T-Cell
4
Lymphoma
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Recurrence
2
Lymphoma, T-Cell, Peripheral
2
Leukemia
2
Squamous Cell Carcinoma of Head and Neck
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Lymphoma, Follicular
1
Immunoblastic Lymphadenopathy
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Enteropathy-Associated T-Cell Lymphoma
1
Burkitt Lymphoma
1
Interventions
Cyclophosphamide
241
Rituximab
223
Etoposide
138
Filgrastim
113
Vincristine
112
Doxorubicin
104
Prednisone
90
Cytarabine
90
Methotrexate
79
fludarabine phosphate
77
Radiotherapy
76
Peripheral Blood Stem Cell Transplantation
71
Melphalan
71
Busulfan
60
Tacrolimus
48
Dexamethasone
48
Mycophenolic Acid
46
Carmustine
46
Granulocyte Colony-Stimulating Factor
44
fludarabine
43
Antilymphocyte Serum
40
Ifosfamide
38
sargramostim
34
Whole-Body Irradiation
34
Cyclosporine
33
Bortezomib
32
Gemcitabine
30
Methylprednisolone
27
Bendamustine Hydrochloride
27
Lenalidomide
25
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 2
×
Lymphoma
×
duvelisib
×
Clear all
NCT03372057
2025-03-07
PRIMO
SecuraBio
Phase 2
Completed
156 enrolled
21 charts
NCT03370185
2023-02-28
BRIO
SecuraBio
Phase 2
Withdrawn
NCT02605694
2021-03-17
FRESCO
SecuraBio
Phase 2
Withdrawn